Communications and Marketing

A growth factor for blood vessels as a protective factor for metastatic tumor cells

No. 35 | 26/05/2020 | by Rei

In cancer patients with solid tumors, metastasis – the dissemination of cells from the primary tumor – is the most common cause of death. This is particularly true in the case of malignant melanoma. Scientists from the German Cancer Research Center (DKFZ) and the University of Heidelberg's Medical Faculty Mannheim have examined tumor samples from patients and have discovered a potential new target for therapy and have discovered a potential new target for treatment, at least in a special group of melanoma patients whose tumor cells produce the growth factor angiopoietin-2. The production of the growth factor in cancer cells was particularly evident in those melanomas that formed metastases. In further investigations in mice, the researchers demonstrated that tumor cells that produce angiopoietin-2 are protected against cell stress and thus have an advantage in metastasis.

​Preclinical melanoma model growing in the skin used to study the effect of tumor cell Angpt2 on metastasis (green = tumor cells; red = blood vessels; blue = lymphatic vessels)
© DKFZ/Augustin

Melanomas are one of the tumors that metastasize at a particularly early stage. Metastasis is also the most common cause of death in patients with malignant melanoma, so preventing this devastating outcome is a key goal of tomorrow's cancer treatment. Hellmut Augustin, Moritz Felcht, and their colleagues from DKFZ and the University of Heidelberg's Medical Faculty Mannheim have now discovered the protein angiopoietin-2 (Angpt2) as a possible new target of treatment to prevent metastasis from occurring. The scientists were previously familiar with Angpt2 as a factor that steers the formation of (tumor) vasculature.

Back in 2009, the researchers in Augustin's team identified Angpt2 as a biomarker to predict the progression of melanomas. Angpt2 levels in the blood are increased particularly in those melanoma patients whose tumors have metastasized. Up to now, Angpt2 was seen as a factor that is produced by endothelial cells – in other words, the cells that line the inside of the blood vessels. Although there have been occasional reports that tumor cells also produce Angpt2, there have not previously been any studies that examine how often this occurs and what consequences it has.

In the present study, the scientists investigated the role of Angpt2 produced by tumor cells. Studies conducted on tumor samples from patients showed that the production of Angpt2 in cancer cells is particularly evident in those melanomas that metastasize. Investigations in mice based on this observation demonstrated that Angpt2 in these tumors does not stimulate the formation of new vessels. "If we switch off Angpt2 in the tumor cells in mice, we do not observe any change in the blood vessels; instead, we see that more cancer cells die," explained lead author Ashik Ahmed Abdul Pari. "At the same time, we find fewer metastases in these animals." The scientists discovered the reason for this in further studies: Without Angpt2, the tumor cells were more sensitive to cell stress and died.

"Our observations were initially made in mice, but it would seem plausible that the situation is comparable in melanoma patients. However, further studies are needed to prove this," remarked principal investigator Moritz Felcht. "This means that we might have identified a new target for treatment in the group of patients with a considerably higher level of Angpt2 produced by the tumor cells."

Abdul Pari AA, Singhal M, Hübers C, Mogler C, Schieb B, Gampp A, Gengenbacher N, Reynolds LE, Terhardt D, Géraud C, Utikal J, Thomas M, Goerdt S, Hodivala-Dilke KM, Augustin HG, Felcht M. Tumor cell-derived angiopoietin-2 promotes metastasis in melanoma. Cancer Res. 2020 Apr 17. pii: canres.2660.2019. doi: 10.1158/0008-5472.CAN-19-2660. [Epub ahead of print]

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Tumour Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS